COMMUNIQUÉS West-GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
06/05/2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
06/05/2024
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of [...]
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
06/05/2024
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due [...]
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
06/05/2024
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) [...]
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
06/05/2024
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD [...]
A Message to Our Valued Stakeholders - We're Here for the Long Haul
06/05/2024
SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today addresses the recent market fluctuations in its [...]
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
06/05/2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
06/05/2024
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal [...]
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
06/05/2024
Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of [...]
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia
06/05/2024
Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing [...]
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees
06/05/2024
MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased [...]
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
06/05/2024
POMPANO BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived [...]
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
06/05/2024
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “ [...]
Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2024 Financial Results on May 15, 2024
06/05/2024
CINCINNATI, May 06, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its [...]
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
06/05/2024
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4. [...]
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
06/05/2024
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the [...]
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06/05/2024
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced [...]
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
06/05/2024
$6.5 million in upfront gross proceeds with the potential to receive up to an additional $11.5 million in potential warrant exercise proceeds for an aggregate of up to approximately $18 million in total gross proceeds [...]
Orion Corporation: Managers’ transactions – Karen Lykke Sørensen
06/05/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Karen Lykke Sørensen Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Pages